Alnylam Pharmaceuticals Inc (ALNY) — Cash Flow-to-Debt Ratio
Alnylam Pharmaceuticals Inc (ALNY) has a Cash Flow-to-Debt Ratio of 0.04x as of December 2025, meaning its operating cash flow of $163.56 Million could theoretically repay 0% of its total liabilities ($4.18 Billion) in one year. See Alnylam Pharmaceuticals Inc free cash flow ratio to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Alnylam Pharmaceuticals Inc Cash Flow-to-Debt Ratio (2002–2025)
Historical debt coverage capacity for Alnylam Pharmaceuticals Inc across 24 annual periods. Also explore ALNY net assets growth trend to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Alnylam Pharmaceuticals Inc (2002–2025)
Year-by-year debt coverage analysis for Alnylam Pharmaceuticals Inc. For market capitalisation and broader financial context, see Alnylam Pharmaceuticals Inc market cap and net worth.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.13x | $524.08 Million | $4.18 Billion | ▲ +6398.7% |
| 2024 | 0.00x | $-8.31 Million | $4.17 Billion | ▼ -107.7% |
| 2023 | 0.03x | $104.16 Million | $4.05 Billion | ▲ +117.6% |
| 2022 | -0.15x | $-541.27 Million | $3.70 Billion | ▲ +30.4% |
| 2021 | -0.21x | $-641.69 Million | $3.06 Billion | ▲ +18.3% |
| 2020 | -0.26x | $-614.96 Million | $2.39 Billion | ▲ +11.6% |
| 2019 | -0.29x | $-278.43 Million | $956.44 Million | ▲ +85.9% |
| 2018 | -2.06x | $-562.62 Million | $272.84 Million | ▼ -23.0% |
| 2017 | -1.68x | $-382.79 Million | $228.30 Million | ▼ -86.7% |
| 2016 | -0.90x | $-307.70 Million | $342.59 Million | ▲ +42.2% |
| 2015 | -1.55x | $-189.14 Million | $121.80 Million | ▼ -34.4% |
| 2014 | -1.16x | $-165.64 Million | $143.33 Million | ▼ -152.8% |
| 2013 | -0.46x | $-68.66 Million | $150.18 Million | ▲ +39.3% |
| 2012 | -0.75x | $-115.61 Million | $153.47 Million | ▼ -41.8% |
| 2011 | -0.53x | $-87.07 Million | $163.92 Million | ▼ -48.0% |
| 2010 | -0.36x | $-84.34 Million | $235.03 Million | ▼ -50.9% |
| 2009 | -0.24x | $-72.14 Million | $303.42 Million | ▼ -228.0% |
| 2008 | 0.19x | $65.49 Million | $352.55 Million | ▼ -72.2% |
| 2007 | 0.67x | $196.52 Million | $294.62 Million | ▲ +205.2% |
| 2006 | -0.63x | $-24.63 Million | $38.83 Million | ▼ -40.7% |
| 2005 | -0.45x | $-16.48 Million | $36.57 Million | ▲ +54.0% |
| 2004 | -0.98x | $-19.57 Million | $19.96 Million | ▼ -372.9% |
| 2003 | -0.21x | $-12.83 Million | $61.89 Million | ▼ -236.6% |
| 2002 | -0.06x | $-1.28 Million | $20.76 Million | — |